Parathyroid hormone-related protein of malignancy: Immunohistochemical and biochemical studies in normocalcaemic and hypercalcaemic patients with cancer

S H Ralston, J Danks, J Hayman, W D Fraser, C S Stewart, T J Martin

Abstract

Immunohistochemical staining for parathyroid hormone-related protein was performed in 27 tumours from 19 normocalcaemic and eight hypercalcaemic patients with cancer. All the tumours from hypercalcaemic patients stained positively for the protein, as did 17 tumours from normocalcaemic patients. Only hypercalcaemic patients had biochemical evidence of increased bone resorption and abnormalities of renal tubular reabsorption of calcium and phosphate, consistent with the presence of parathyroid hormone-related protein. While tumour mass was higher in hypercalcaemic patients, only one of the initially normocalcaemic patients with positively staining tumours subsequently went on to develop hypercalcaemia and more advanced disease.

These data confirm the importance of parathyroid hormone-related protein as a mediator of humoral hypercalcaemia in patients with solid tumours and suggest that low tumour mass may be one reason why serum calcium values are not increased in all patients with tumours containing parathyroid hormone-related protein. None of the less normocalcaemic, despite tumour progression in patients whose tumours stained positively for parathyroid hormone-related protein, suggests that other factors may also be important, such as differences in the rate of secretion of the protein by different tumours, or the production of different forms of parathyroid hormone-related protein with varying biological effects.

Parathyroid hormone-related protein has been implicated as an important mediator of humoral hypercalcaemia in malignancy. Because of its homology with parathyroid hormone (PTH) at the amino-terminus, parathyroid hormone-related protein mimics much of the behaviour of PTH on bone and kidney and so reproduces the "hyperparathyroid-like" biochemical abnormalities which are typical of hypercalcaemia associated with cancer. In previous studies parathyroid hormone-related protein and its messenger RNA were shown in tumour tissue from both normocalcaemic and hypercalcaemic cancer patients using immunohistochemical techniques, Northern blot analysis, and in situ hybridisation. In addition to its role as a mediator of hypercalcaemia in malignancy, parathyroid hormone-related protein has also been suggested as an important calcium regulator in the fetus and it has been shown in adult parathyroid adenomas and hyperplasia. Many normal tissues also express parathyroid hormone-related protein, including lactating mammary gland, keratinocytes, fibroblasts, brain, various endocrine tissues and gastric mucosa.

It is at present unclear why only a proportion of patients with tumours that produce parathyroid hormone-related protein are hypercalcaemic, given the potent bone resorbing and calcium increasing effects of parathyroid hormone-related protein in vitro and in vivo. Various reasons have been suggested, including failure of parathyroid hormone-related protein translation from its messenger RNA, low levels of protein secretion, low tumour mass, concomitant secretion of other bone resorbing factors which act synergistically with parathyroid hormone-related protein to cause hypercalcaemia, and the ability of homeostatic mechanisms to preserve normocalcaemia despite the release of the protein.

To investigate further the association between the presence of parathyroid hormone-related protein in tumours and the development of hypercalcaemia, we carried out immunohistochemical staining for parathyroid hormone-related protein in a series of tumours from normocalcaemic and hypercalcaemic patients with cancer who also were evaluated biochemically for evidence of the protein's effects on bone and kidney.

Methods

Tumour tissue was available from 27 patients as the result of procedures performed during the course of routine management and provided that informed consent to participating in the study had been given. Eight patients were hypercalcaemic at the time of study (serum calcium adjusted for albumin of 2.70 mmol/l or greater) and 19 were normocalcaemic. Eleven of the patients who were initially normocalcaemic were subsequently
followed up by regular checks of serum calcium until just before death; three of these patients developed hypercalcaemia and eight remained normocalcaemic. In the remaining eight normocalcaemic patients no further measurements of serum calcium were available, either because the patients were lost to follow up (n = 5), or because they died of early complications after surgical resection of lung tumours (n = 3); arrhythmia n = 1, pulmonary embolism n = 1; pneumonia n = 1).

Immunohistochemical staining for parathyroid hormone-related protein was performed on formalin fixed, paraffin wax embedded sections. The antiserum used for immunostaining was prepared in New Zealand white rabbits immunized against synthetic parathyroid hormone-related protein (1–34) as described previously.13 This antiserum has been fully characterised in previous studies13,15–17 and is specific to the (1–34) portion of the parathyroid hormone-related protein molecule; it shows no cross reactivity with PTH or PTH-derived peptides in Western blots, or at high concentrations in blocking biological activity.

A positive control was included in every experiment consisting of a squamous carcinoma of the skin.12 Standard negative controls for method and antibody were used as previously described,12,13 including alternating deletions of the antibody layers, primary antiserum, second antibody and peroxidase-antiperoxidase complex; and substitution of non-immune and unrelated immune rabbit serum for primary antiserum and preabsorption of the antibody overnight with parathyroid hormone-related peptide (1–34) or PTH (1–34) peptides. All of these controls abolished staining, except for the overnight preabsorption with PTH (1–34) which had no effect.

In all patient samples the pattern of parathyroid hormone-related protein staining was graded blind by an observer on a three point scale: 0 = no staining (negative); definite staining of cytoplasm of cells (positive); dark staining of cytoplasm (strongly positive).

Assessment of tumour mass at the time when the tissue samples were obtained was achieved by a combination of direct measurement of the dimensions of excised tumour specimens or by the appearances on computed tomography scans; for the purposes of this study the tumours were assumed to be perfect spheres, with a volume given by the equation \( \frac{4}{3} \pi d^3 \), where \( \pi = 3:141 \) and \( d \) = maximum diameter of the tumour.

Biochemical analyses were made using standard autoanalyzer techniques (Technicon, Tarrytown, USA) on blood samples and second-voided urine samples obtained after an overnight fast. Total serum calcium was adjusted for albumin as previously described (reference range 2.2–2.6 mmol/l).18 Plasma intact PTH (1–84) concentrations were measured using a two-site immunoradiometric assay19 (reference range 1.0–5.0 pmol/l). Urine cyclic adenosine mono-phosphate (cAMP) was measured using a radioimmunoassay as previously described.20 The following derived variables were calculated from fasting blood and urine measurements: molar urinary ratios of calcium to creatinine (reference range = <0.50); hydroxyproline to creatinine (reference range = <0.030); and cyclic AMP to creatinine (reference range = 0.1–0.65). Renal tubular reabsorption of phosphate (reference range 0.80–1.35) was derived from a nomogram21 and renal tubular reabsorption of calcium, corrected for urinary sodium excretion (reference range 1.98–2.76) by the method of Need et al.22

Student's t test was used for statistical analysis.

**Results**

Relevant clinical and biochemical details are shown in table 1 for normocalcaemic and hypercalcaemic subgroups (serum calcium less than or equal to and greater than 2.70 mmol/l, respectively). The hypercalcaemic patients had significantly lower serum phosphate, renal tubular reabsorption of phosphate values, and higher hydroxyproline:creatinine; calcium: creatine ratios and renal tubular reabsorption of calcium, corrected for urinary sodium excretion, values than the normocalcaemic patients. Cyclic AMP:creatinine values were also higher in the hypercalcaemic patients, but the difference between the groups was not significant. Four of the normocalcaemic patients had increased cyclic AMP: creatine values (0.66, 0.75, 0.81, 0.97) and three of the hypercalcaemic patients had normal values (0.38, 0.50, 0.56). There was no significant correlation between tumour mass (see below) and cyclic AMP: creatine values (r = 0.137, p = NS). Plasma (1–84) PTH values (not shown) were undetectable in all hypercalcaemic patients and were either undetectable or lay within the low-normal range in normocalcaemic patients. The mean (SEM) tumour mass was 61.5 (11.4) cm\(^3\) in the normocalcaemic patients (range 1.8–179.6) cm\(^3\).

<table>
<thead>
<tr>
<th>Table 1 Relevant clinical and biochemical details in study group</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Normocalcaemic</strong></td>
</tr>
<tr>
<td>(n = 19)</td>
</tr>
<tr>
<td>Serum calcium (mmol/l)</td>
</tr>
<tr>
<td>Serum phosphate (mmol/l)</td>
</tr>
<tr>
<td>Serum creatinine (mmol/l)</td>
</tr>
<tr>
<td>Urinary cyclic AMP: creatine (mmol/mmol)</td>
</tr>
<tr>
<td>Urinary hydroxyproline: creatine (mmol/mmol)</td>
</tr>
<tr>
<td>Urinary calcium: creatine (mmol/mmol)</td>
</tr>
<tr>
<td>Tubular reabsorption of calcium (mmol/l GFR)</td>
</tr>
<tr>
<td>Tubular reabsorption of phosphate (mmol/l GFR)</td>
</tr>
</tbody>
</table>

*<p < 0.05
**<p < 0.01
****<p < 0.001

Significance difference between groups.

Tumour types were:

Hypercalcaemic: squamous lung = 7

Metastases: renal = 1

Normocalcaemic: squamous lung = 11

adenocarcinoma = 1

small cell lung = 1

breast = 1

anaplastic = 1

GFR = glomerular filtration rate.
compared with 210·0 (52·2) cm³ (range 65·4–523·6) in the hypercalcaemic patients (p < 0·02). In nine normocalcaemic patients whose tumours were excised there was no significant change in serum calcium values (before surgery mean (SEM) = 2·52 (0·01) mmol/l; after surgery 2·51 (0·01) mmol/l, p = NS). In contrast, serum calcium values fell significantly in five hypercalcaemic patients whose tumours were excised (before surgery = 3·02 (0·09) mmol/l; after surgery = 2·44 (0·03) mmol/l, p < 0·02).

Table 2 shows the pattern of immunohistochemical staining for parathyroid hormone-related protein in normocalcaemic and hypercalcaemic patients. All eight of the tumours from hypercalcaemic patients stained strongly positively for the protein. Of the 19 tumours from normocalcaemic patients, 11 (57%) stained strongly positive, six stained positive, and two negative (χ² = 4·78; p < 0·05). In the normocalcaemic patients there was no apparent relation between the pattern of parathyroid hormone-related protein staining and subsequent development of hypercalcaemia; in 11 patients where detailed follow up checks of serum calcium concentration were performed, three became hypercalcaemic (two negative tumours, one positive tumour) and eight remained normocalcaemic (four strongly positive, four positive). All three of the normocalcaemic patients who subsequently became hypercalcaemic had biochemical evidence of parathyroid hormone-related protein-mediated hypercalcaemia when serum calcium values increased; all were hypophosphataemic and one (with an initially negatively staining tumour) was also found to have reduced values of tubular reabsorption of phosphate, raised values of tubular reabsorption of calcium, corrected for urinary sodium excretion, and very high cyclic AMP:creatinine concentrations.

**Discussion**

Biochemical evaluation of hypercalcaemic patients in this study showed features consistent with the actions of parathyroid hormone-related protein on bone and kidney: bone resorption, renal tubular reabsorption of calcium, and cyclic AMP excretion were all increased and serum phosphate and renal tubular reabsorption of phosphate reduced. These findings concur with previous clinical observations and, along with the demonstration of parathyroid hormone-related protein in tumour tissue by immunostaining, emphasise the importance of the protein as the predominant humoral mediator of hypercalcaemia in malignancy.

The increased cyclic AMP: creatinine values which we noted in four out of 19 (21%) normocalcaemic patients confirm the findings

![Example of strongly positive staining for parathyroid hormone-related protein in a squamous lung carcinoma from a hypercalcaemic patient.](http://jcp.bmj.com/)
of previous workers and suggest that parathyroid hormone-related protein may also be released into the systemic circulation in normocalcaemic patients with cancer at concentrations which are presumably too low to cause a sustained increase in blood calcium activity. While measurement of plasma parathyroid hormone-related protein was not technically possible when our patients presented, it has been shown in a recent study that plasma concentrations may be increased in up to 25% of normocalcaemic cancer patients using a sensitive immunoradiometric assay.

The present findings, together with previous immunohistochemical and in situ hybridisation data, show that parathyroid hormone-related protein can be detected in tumours from both normocalcaemic and hypercalcaemic patients with cancer. Low tumour mass is an obvious explanation for the absence of hypercalcaemia in patients with positively staining tumours, and, indeed, tumour mass at the time of presentation was significantly lower in the normocalcaemic compared with the hypercalcaemic group. This is unlikely to have been the only factor in determining the occurrence of hypercalcaemia, however, as some normocalcaemic patients who exhibited positive or strongly positive staining for parathyroid hormone-related protein had tumours of equal size to those of the hypercalcaemic patients, and only one went on to develop hypercalcaemia despite progression of the tumours to a terminal stage.

Alternative explanations for the failure of such patients to develop hypercalcaemia include differences in the structure, biological effects, or rate of parathyroid hormone-related protein secretion between the normalcaemic and hypercalcaemic subgroups. Several different types of parathyroid hormone-related protein with common amino-terminal, but differing carboxyl-terminal, sequences may be generated as the result of differential splicing of differing transcripts encoding a parathyroid hormone-related protein. These different forms may have different biological properties and may be released into the systemic circulation in different proportions in different patients. Indeed, it has been shown that the ratio of carboxyl-terminal to amino-terminal sequence may be different in patients with hypercalcaemia and normocalcaemia.

The failure of parathyroid hormone-related protein to cause hypercalcaemia in some patients who subsequently developed biochemical evidence of hypercalcaemia is puzzling, as we have previously reported identification of cytoplasmic parathyroid hormone-related protein in normal skin and in 100% of a series of squamous carcinomas from normocalcaemic patients. This most probably relates to technical factors such as loss of the antigen during fixation, although expression of parathyroid hormone-related protein in these patients at a later stage in tumour development, or selective parathyroid hormone-related protein expression in some but not all areas of tumour tissue, would also be possible. Unfortunately, we were unable to obtain further tissue in either case to investigate these possibilities.


21 Logue FC, Fraser WD, O'Reilly D St J, Beastall GH. The circadian rhythm of intact parathyroid hormone (1–84) and nephrogenous cyclic adenosine monophosphate in normal man. J Endocrinol 1989;121:R1–R3.
Parathyroid hormone-related protein of malignancy: immunohistochemical and biochemical studies in normocalcaemic and hypercalcaemic patients with cancer.

S H Ralston, J Danks, J Hayman, W D Fraser, C S Stewart and T J Martin

doi: 10.1136/jcp.44.6.472

Updated information and services can be found at:
http://jcp.bmj.com/content/44/6/472

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/